Cost-utility of cardiac contractility modulation in patients with heart failure with reduced ejection fraction in Italy.

ABSTRACT:

Aims

Cardiac contractility modulation (CCM) is a device therapy for heart failure, based on the delivery of high-voltage biphasic impulses to the right ventricular septum during the myocardial absolute refractory period. This study evaluated the cost-effectiveness of CCM therapy plus optimal medical therapy (OMT) vs. OMT alone in patients with heart failure with reduced ejection fraction.

Methods and results

A Markov model with a lifespan time horizon was developed to assess the cost-utility using the FIX trials as main data sources. A deterministic sensitivity analysis and a probabilistic sensitivity analysis were run to analyse the decision uncertainty in the model through cost-effectiveness acceptability curve (CEAC) and cost-effectiveness acceptability frontier (CEAF). V

SUBMITTER: Narducci ML 

PROVIDER: S-EPMC10804153 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature